Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

BUY
$32.76 - $39.56 $1.26 Million - $1.52 Million
38,496 Added 236.06%
54,804 $1.92 Million
Q4 2023

Feb 14, 2024

BUY
$14.5 - $38.0 $1,218 - $3,192
84 Added 0.52%
16,308 $619,000
Q3 2023

Nov 09, 2023

BUY
$15.75 - $26.31 $33,957 - $56,724
2,156 Added 15.33%
16,224 $297,000
Q2 2023

Aug 14, 2023

SELL
$16.96 - $27.82 $165,784 - $271,940
-9,775 Reduced 41.0%
14,068 $365,000
Q1 2023

May 15, 2023

BUY
$18.45 - $27.14 $110,072 - $161,917
5,966 Added 33.37%
23,843 $449,000
Q4 2022

Feb 13, 2023

BUY
$20.18 - $33.33 $80,518 - $132,986
3,990 Added 28.73%
17,877 $440,000
Q3 2022

Nov 14, 2022

SELL
$11.58 - $24.73 $7,538 - $16,099
-651 Reduced 4.48%
13,887 $250,000
Q2 2022

Aug 11, 2022

SELL
$8.52 - $25.26 $471,011 - $1.4 Million
-55,283 Reduced 79.18%
14,538 $165,000
Q1 2022

May 13, 2022

SELL
$19.89 - $43.18 $70,171 - $152,339
-3,528 Reduced 4.81%
69,821 $1.56 Million
Q4 2021

Feb 11, 2022

BUY
$26.75 - $46.02 $74,070 - $127,429
2,769 Added 3.92%
73,349 $3.2 Million
Q3 2021

Nov 04, 2021

SELL
$25.18 - $37.81 $13,093 - $19,661
-520 Reduced 0.73%
70,580 $2.35 Million
Q2 2021

Aug 11, 2021

BUY
$14.69 - $27.52 $964,545 - $1.81 Million
65,660 Added 1206.99%
71,100 $1.96 Million
Q1 2021

May 13, 2021

SELL
$16.27 - $41.26 $4,246 - $10,768
-261 Reduced 4.58%
5,440 $109,000
Q4 2020

Feb 16, 2021

BUY
$15.96 - $50.0 $90,987 - $285,050
5,701 New
5,701 $188,000

Others Institutions Holding INBX

# of Institutions
1
Shares Held
18.6K
Call Options Held
0
Put Options Held
0

About Inhibrx, Inc.


  • Ticker INBX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 39,057,700
  • Market Cap $570M
  • Description
  • Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcin...
More about INBX
Track This Portfolio

Track Deutsche Bank Ag\ Portfolio

Follow Deutsche Bank Ag\ and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Deutsche Bank Ag\, based on Form 13F filings with the SEC.

News

Stay updated on Deutsche Bank Ag\ with notifications on news.